JP5137185B2 - L−2−チオヒスチジン又はその誘導体の1つの化粧組成物における脱色剤としての使用 - Google Patents
L−2−チオヒスチジン又はその誘導体の1つの化粧組成物における脱色剤としての使用 Download PDFInfo
- Publication number
- JP5137185B2 JP5137185B2 JP2007337703A JP2007337703A JP5137185B2 JP 5137185 B2 JP5137185 B2 JP 5137185B2 JP 2007337703 A JP2007337703 A JP 2007337703A JP 2007337703 A JP2007337703 A JP 2007337703A JP 5137185 B2 JP5137185 B2 JP 5137185B2
- Authority
- JP
- Japan
- Prior art keywords
- cosmetic composition
- thiohistidine
- agent
- cosmetic
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 46
- 239000002537 cosmetic Substances 0.000 title claims description 44
- NYCOUFMGUFTKTL-BYPYZUCNSA-N (2s)-2-amino-3-(2-sulfanylideneimidazol-4-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=NC(=S)N=C1 NYCOUFMGUFTKTL-BYPYZUCNSA-N 0.000 title claims description 33
- 239000007854 depigmenting agent Substances 0.000 title claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000007844 bleaching agent Substances 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 claims description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 229950010033 ebselen Drugs 0.000 claims description 2
- 229960003720 enoxolone Drugs 0.000 claims description 2
- 229940074774 glycyrrhizinate Drugs 0.000 claims description 2
- 235000009569 green tea Nutrition 0.000 claims description 2
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 claims description 2
- 229960004135 idebenone Drugs 0.000 claims description 2
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical group 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 claims description 2
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 241000208720 Nepenthes Species 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 17
- 238000000034 method Methods 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 12
- 238000004042 decolorization Methods 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 210000002615 epidermis Anatomy 0.000 description 9
- FVNKWWBXNSNIAR-BYPYZUCNSA-N (2s)-2-amino-3-(2-sulfanylidene-1,3-dihydroimidazol-4-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CNC(=S)N1 FVNKWWBXNSNIAR-BYPYZUCNSA-N 0.000 description 8
- MDYOLVRUBBJPFM-UHFFFAOYSA-N tropolone Chemical compound OC1=CC=CC=CC1=O MDYOLVRUBBJPFM-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 6
- 229960004705 kojic acid Drugs 0.000 description 6
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 6
- 210000002752 melanocyte Anatomy 0.000 description 6
- 238000000399 optical microscopy Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 229940093497 ergothioneine Drugs 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 150000004788 tropolones Chemical class 0.000 description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- 238000004061 bleaching Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229940085262 cetyl dimethicone Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- -1 tropolone compound Chemical class 0.000 description 2
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- FVNKWWBXNSNIAR-UHFFFAOYSA-N 2-amino-3-(2-sulfanylidene-1,3-dihydroimidazol-4-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CNC(S)=N1 FVNKWWBXNSNIAR-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- SSISHJJTAXXQAX-UHFFFAOYSA-N 5-[2-carboxy-2-(trimethylazaniumyl)ethyl]-1h-imidazole-2-thiolate Chemical compound C[N+](C)(C)C(C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 241000254171 Curculionidae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 229920002266 Pluriol® Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- 229910010413 TiO 2 Inorganic materials 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003712 decolorant Substances 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- IIGMITQLXAGZTL-UHFFFAOYSA-N octyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC IIGMITQLXAGZTL-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940100518 polyglyceryl-4 isostearate Drugs 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 125000003748 selenium group Chemical class *[Se]* 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Description
−図1:L−DOPA
−図2:コウジ酸
−図3:エルゴチオネイン
−図4:L−2−チオヒスチジン(50μg/ml)
−図5:L−2−チオヒスチジン(150μg/ml)
39歳の女性の形成外科手術に由来する凍結乳房表皮(参照P148AB39)を、37℃で1時間45分間、2N NaBr中で保温して剥離させる。これらをホルマリン処理固定液で固定し、緩衝剤で処理し、すすいでからL−DOPA/有効成分溶液の容積/容積混合物と接触させる。保温後、それらをすすいでから封入剤を用いてスライドとカバーガラスの間に置く。
a)DOPA対照標準(添付の図1を参照)では、メラニン細胞を明確に見ることができ、十分に色素沈着している。
b)比較脱色剤である150μg/mlの濃度のコウジ酸を加えた系(図2を参照)では、メラニン細胞はほんの少し見えるだけであり、したがってかなり優れた脱色作用(この場合、75%に近い)があることが分かる。
c)比較脱色剤である50μg/mlの濃度のエルゴチオネインを加えた系(図3を参照)では、メラニン細胞が相当見られ、まだかなり色素沈着していることが分かる。45%に近い軽い脱色作用が観察される。
d)本発明による50μg/mlの濃度のL−2−チオヒスチジンを加えた系(図4を参照)では、同じ濃度のエルゴチオネインを加えた系(図3を参照)よりもメラニン細胞が見えなくなっているが分かる。したがって脱色作用(この場合60%)は優れている。
e)150μg/mlの濃度で脱色剤としてL−2−チオヒスチジンを使用した系(図5を参照)では、非常にわずかしか色素沈着していないので、メラニン細胞は非常にわずかしか見えなくなっていることが分かる。脱色作用はこの場合75%、すなわち脱色作用は非常に優れている。図1から5で見ることができる脱色作用は、一連の3つの試験に関してメラニン粒子を数えることにより統計学的に定量化した。値を以下の表に示す。その中では、ステューデント検定で得られた値を、同じ濃度におけるエルゴチオネイン対L−2−チオヒスチジン及びコウジ酸対L−2−チオヒスチジンについて示してある。ステューデント検定は、得られた値が0.05未満である場合に有意であると言われる。
1.脱色剤
L−2−チオヒスチジン 0.5
2.賦形剤
グリコール 3
ポリアクリルアミド/C13−14イソパラフィン/laureth−7(Sepigel 305) 3
水添ひまし油(Cremophor CO 60) 2
ポリエチレングリコール(Pluriol E 1505) 1.5
防腐剤 0.5
濃縮香料 0.3
水 89.2
本発明による脱色乳液の形態の化粧組成物
脱色剤
L−2−チオヒスチジン 0.01
賦形剤
Steareth−21(Brij 721) 2.5
ステアリン酸グリセリル(Tegin 90) 1.1
ステアリルアルコール 5
グリセロール・トリカプリレート/カプリレート 20
ブチレングリコール 3
グリセロール 2
防腐剤 0.5
濃縮香料 0.5
水 100にするための残量(qsp 100)
本発明による脱色ローションの形態の化粧組成物
脱色剤
L−2−チオヒスチジン 0.001
賦形剤
ブチレングリコール 3
EDTA 0.1
可溶化剤 1
濃縮香料 0.3
アルコール 5
水 残量(qsp)
肌の色を明るくする粉末の形態の本発明による化粧組成物
脱色剤
L−2−チオヒスチジン 0.005
賦形剤
タルク 20
雲母 20
絹雲母 20
顔料 8
有機粉末(ナイロン) 20
シリカ 91.005
鉱油又はシリコーン 3
明色化用(lightening)メイクアップファンデーションの形態の本発明による化粧組成物
脱色剤
L−2−チオヒスチジン 0.0001
賦形剤
イソステアリン酸ポリグリセリル−4/セチルジメチコン/ラウリン酸ヘキシル 5.1
シクロペンタシロキサン/シクロヘキサシロキサン 5.0
セチルジメチコン 1.0
トリ(カプリル/カプリン酸)グリセリル 2.2
ステアリン酸オクチル 1.4
鉱油 6.5
水添ひまし油 1.2
蜜ろう 0.8
ポリメタクリル酸メチル 1.1
Fe2O3 0.45
TiO2 5.2
NaCl 0.6
濃縮香料 0.1
水 残量(qsp)
Claims (9)
- ヒトの皮膚の脱色剤としてL−2−チオヒスチジンを含む、脱色剤。
- 0.0001重量%から1重量%のL−2−チオヒスチジンを含む、皮膚上の色素によるシミを薄くするか取り除き及び/又は皮膚を明るくするための化粧組成物。
- 前記化粧組成物が、0.001重量%から0.1重量%のL−2−チオヒスチジンを含む請求項2記載の化粧組成物。
- 前記化粧組成物が、少なくとも1の他の脱色剤をも含む、請求項2又は3に記載の化粧組成物。
- 前記化粧組成物が、少なくとも1の他の化粧活性剤をも含む、請求項2から4のいずれか一項に記載の化粧組成物。
- 前記他の化粧活性剤が酸化防止剤である、請求項5に記載の化粧組成物。
- 前記酸化防止剤が、ポリフェノール、エブセレン、ビタミンE及びイデベノンから選択される、請求項6に記載の化粧組成物。
- 前記他の化粧活性剤が無痛化剤である、請求項5から7のいずれか一項に記載の化粧組成物。
- 前記無痛化剤がコガネバナの抽出物、ウツボグサの抽出物、緑茶の抽出物、グリシルレチン酸、グリチルリチン酸アンモニウム、グリチルリチン酸カリウム及びグリチルレチン酸ステアリルから選択される、請求項8に記載の化粧組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0656063A FR2910808B1 (fr) | 2006-12-29 | 2006-12-29 | Utilisation en cosmetique de la l-2-thiohistidine ou d'un de ses derives comme agent depigmentant. |
FR0656063 | 2006-12-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008189657A JP2008189657A (ja) | 2008-08-21 |
JP5137185B2 true JP5137185B2 (ja) | 2013-02-06 |
Family
ID=38458466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007337703A Active JP5137185B2 (ja) | 2006-12-29 | 2007-12-27 | L−2−チオヒスチジン又はその誘導体の1つの化粧組成物における脱色剤としての使用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7935359B2 (ja) |
EP (1) | EP1938793B1 (ja) |
JP (1) | JP5137185B2 (ja) |
KR (1) | KR101496227B1 (ja) |
CN (1) | CN101209229B (ja) |
FR (1) | FR2910808B1 (ja) |
HK (1) | HK1119088A1 (ja) |
RU (1) | RU2007149263A (ja) |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5527883B2 (ja) | 1971-10-12 | 1980-07-24 | ||
JPS5846462B2 (ja) * | 1978-08-21 | 1983-10-17 | 川崎重工業株式会社 | セメントクリンカの焼成装置 |
JPS56147704A (en) * | 1980-04-07 | 1981-11-16 | Rowaale Keshohin Kk | Dermatological composition |
JPS56147104A (en) | 1980-04-17 | 1981-11-14 | Keiaishiya Mikami Seisakusho:Kk | Reinforced mirror made of synthetic resin |
JPS5844442A (ja) | 1981-09-11 | 1983-03-15 | Fujitsu Ltd | 電子写真用感光材料 |
JPS6016907A (ja) * | 1983-07-07 | 1985-01-28 | Pola Chem Ind Inc | 美白化粧料 |
JPH0449216A (ja) * | 1990-06-19 | 1992-02-18 | Taisho Pharmaceut Co Ltd | メラニン抑制剤 |
EP0483426A1 (en) * | 1990-11-01 | 1992-05-06 | The Procter & Gamble Company | Thiol heterocyclic deodorant composition and method of deodorization |
FR2707087B1 (fr) * | 1993-06-28 | 1995-10-13 | Bioxytech | Nouveau procédé de préparation de l'ergothionéine. |
FR2714380B1 (fr) * | 1993-12-24 | 1996-05-24 | Bioxytech | Utilisation de dérivés 2-mercapto-imidazole substitués en position 4 (ou 5) comme agents antioxydants, leur procédé de préparation et leurs applications en pharmacie, cosmétique ou alimentaire. |
JPH10501817A (ja) * | 1994-06-15 | 1998-02-17 | ザ、プロクター、エンド、ギャンブル、カンパニー | 哺乳動物皮膚における色素過剰部位のライトニング方法 |
FR2751538B1 (fr) * | 1996-07-26 | 1998-09-11 | Oreal | Utilisation de derives de l'acide n,n'-dibenzyl ethylenediamine n,n'-diacetique comme agents depigmentants |
USH2043H1 (en) * | 1997-05-23 | 2002-08-06 | The Procter & Gamble Company | Skin care compositions |
DE10008907A1 (de) * | 2000-02-25 | 2001-08-30 | Haarmann & Reimer Gmbh | Topische kosmetische Mittel enthaltend benzokondensierte oder heterocyclisch kondensierte 2-Hydrazino-1,3-heteroazole |
FR2809000B1 (fr) | 2000-05-18 | 2002-08-09 | Oreal | Utilisation d'ergothioneine et/ou de ses derives comme agent anti-pollution |
US20030095959A1 (en) * | 2000-11-21 | 2003-05-22 | Access Business Group International Llc. | Topical skin composition |
US7025957B2 (en) * | 2002-09-06 | 2006-04-11 | Desert Whale Jojoba Company | Composition and method to whiten skin |
FR2867384B1 (fr) | 2004-03-15 | 2008-10-17 | Lvmh Rech | Compositions cosmetiques et dermatologiques a activite depigmentante |
EP1748767B1 (en) * | 2004-05-28 | 2011-12-28 | Unigen, Inc. | 1-(3-methyl-2,4-dimethoxyphenyl)-3-(2',4'-dihydroxyphenyl)-propane as a potent tyrosinase inhibitor |
JP4842550B2 (ja) * | 2005-03-08 | 2011-12-21 | 株式会社コーセー | チロシナーゼ活性阻害剤、メラニン産生抑制剤及び美白用皮膚外用剤 |
US20060263320A1 (en) * | 2005-05-17 | 2006-11-23 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using personal care compositions comprising ergothioneine |
US20070092578A1 (en) * | 2005-10-26 | 2007-04-26 | Yasuhiro Itagaki | Skin rejuvinating supplement |
-
2006
- 2006-12-29 FR FR0656063A patent/FR2910808B1/fr active Active
-
2007
- 2007-12-03 EP EP07122141.0A patent/EP1938793B1/fr active Active
- 2007-12-26 RU RU2007149263/15A patent/RU2007149263A/ru not_active Application Discontinuation
- 2007-12-26 KR KR20070137411A patent/KR101496227B1/ko active IP Right Grant
- 2007-12-27 JP JP2007337703A patent/JP5137185B2/ja active Active
- 2007-12-28 CN CN2007103060860A patent/CN101209229B/zh active Active
- 2007-12-28 US US12/005,823 patent/US7935359B2/en active Active
-
2008
- 2008-12-04 HK HK08113192.1A patent/HK1119088A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN101209229A (zh) | 2008-07-02 |
US20080161377A1 (en) | 2008-07-03 |
EP1938793A2 (fr) | 2008-07-02 |
US7935359B2 (en) | 2011-05-03 |
EP1938793A3 (fr) | 2009-03-25 |
FR2910808B1 (fr) | 2009-04-10 |
FR2910808A1 (fr) | 2008-07-04 |
JP2008189657A (ja) | 2008-08-21 |
HK1119088A1 (en) | 2009-02-27 |
KR20080063117A (ko) | 2008-07-03 |
CN101209229B (zh) | 2013-03-20 |
RU2007149263A (ru) | 2009-07-10 |
KR101496227B1 (ko) | 2015-02-26 |
EP1938793B1 (fr) | 2013-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4729343B2 (ja) | 敏感肌又は不耐性皮膚の許容限界を増大させるための少なくとも一のキレート剤を含む組成物の使用 | |
JP5210513B2 (ja) | 化粧料及びそれに含有される抽出物 | |
KR101964809B1 (ko) | No 활성 억제제, 이를 포함하는 항염증 제제, 이를 포함하는 화장품 및 이의 제조방법 | |
Mohammad et al. | Phytocosmeceutical formulation development, characterization and its in-vivo investigations | |
JP4393064B2 (ja) | 白肌をつくるための化粧品成分となるチラミンの使用方法 | |
KR20080070621A (ko) | 신규 피부 관리 조성물 | |
WO2012172199A1 (fr) | Composition a base de camellia japonica et polygonum hydropiper pour protection de la peau | |
JP2005120023A (ja) | 皮膚外用剤 | |
JP2010511021A (ja) | 色素脱失剤としてのガンマアミノ酪酸の利用 | |
JP3590369B2 (ja) | クリプトタンシノンを含むニキビ予防及び治療用化粧料組成物 | |
JP5669436B2 (ja) | 組成物 | |
JP2572730B2 (ja) | 皮膚化粧料 | |
JP2011241164A5 (ja) | ||
JP2000169329A (ja) | 化粧料組成物 | |
JP5137185B2 (ja) | L−2−チオヒスチジン又はその誘導体の1つの化粧組成物における脱色剤としての使用 | |
FR3034667A1 (fr) | Composition cosmetique et/ou dermatologique contre l'acne | |
JPH10279428A (ja) | 化粧料 | |
KR100396476B1 (ko) | 화장품용 크림 조성물 | |
KR20010062535A (ko) | N-에틸옥시카르보닐-4-아미노페놀, 및 아르부틴 또는그의 유도체 및/또는 엘라직산 또는 그의 유도체를함유하는 미용 조성물 | |
KR20030005258A (ko) | 케라틴 물질의 화장용 처리에 있어서의 알콜디하이드로게나아제 저해제의 용도 | |
JP2006213681A (ja) | シワ改善剤 | |
JPH03200708A (ja) | 皮膚外用剤 | |
JP2005314434A (ja) | 生物におけるヒスタミン放出に関連する徴候を減じるための一のキレート剤を含む組成物の使用 | |
KR100364314B1 (ko) | 탈색제로서 미발효된 당밀의 용도 | |
JPH0952817A (ja) | 美白化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080602 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080610 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091126 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120306 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120403 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120626 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120719 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120814 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120911 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121016 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121109 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5137185 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151122 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |